Bifidobacterium infantis M-63
Bifidobacterium longum subsp. infantis M-63 is a well-characterized infant-associated strain studied in randomized controlled trials in newborns and infants, examining its establishment within Bifidobacterium-predominant gut microbiota, which is considered characteristic of breast-fed infants, during weaning and early postnatal periods. A 2025 randomized controlled trial examined inflammatory markers in term infants, and a 2016 randomized controlled trial using M-63 as part of a multispecies mixture examined abdominal pain in children with IBS, though the multispecies design limits strain-specific attribution. In vitro studies have examined human milk oligosaccharide (HMO) metabolism by this strain. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 14 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 7 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
18 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
PMID 42710681 →Bifidobacterium longum subsp. infantis M-63 can reach the neonatal gut following World Health Organization-recommended infant formula preparation at ≥70 °C· Journal of Nutrition · 2026
-
[2]
PMID 42056537 →Effects of Bifidobacterium infantis M-63 on gut environment and bowel function during weaning: RCT· Pediatric Research · 2026
-
[3]
PMID 36986131 →Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial· Nutrients · 2023
-
[4]
PMID 27306945 →A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome· Journal of Clinical Gastroenterology · 2016